Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 285

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 285
---
 to Exhibit 10.12 to the Current Report on Form 8-K/A filed by CERo Therapeutics Holdings,
    Inc. with the Securities and Exchange Commission on February 27, 2024).

    10.15
     
    Securities Purchase Agreement, dated as of March 29, 2024, by and between CERo Therapeutics Holdings,
    Inc. and the investors named therein (incorporated by reference to Exhibit 10.13 to the Annual Report on Form 10-K filed by CERo
    Therapeutics Holdings, Inc. with the Securities and Exchange Commission on April 2, 2024).

115

    10.16
     
    Registration Rights Agreement, dated as of March 29, 2024, by and between CERo Therapeutics Holdings, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.14 to the Annual Report on Form 10-K filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on April 2, 2024).

    10.17+
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Kristen Pierce (incorporated
    by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities and
    Exchange Commission on October 2, 2024).

    10.18+
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Andrew Kucharchuk
    (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities
    and Exchange Commission on October 2, 2024).

    10.19+
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Brian G. Atwood
    (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities
    and Exchange Commission on October 2, 2024).

    10.20
     
    Consulting Agreement, dated September 30, 2024, by and between the Company and Chris Ehrlich (incorporated
    by reference to Exhibit